Free Trial
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel
NASDAQ:ERAS

Erasca Q3 2026 Earnings Date & Estimates

Erasca logo
$14.77 +0.07 (+0.46%)
As of 09:46 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Erasca is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. The conference call is scheduled for November 9, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Erasca in Q3 2026

Erasca is expected to post earnings of -$0.1301 per share. In the same quarter a year earlier Erasca reported -$0.11 per share. Erasca last reported on August 11, 2026, posting -$0.14 per share and missing the -$0.1114 consensus estimate. Erasca has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.1301
Prior-Year EPS
-$0.11

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.14 (Missed by -$0.0286)
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Erasca Q3 2026 Earnings FAQ

Erasca (NASDAQ:ERAS) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Erasca's Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Erasca to post earnings of -$0.1301 per share for Q3 2026.

Erasca Earnings Headlines

Erasca (NASDAQ:ERAS) Shares Down 5.1% - What's Next?
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31088094
Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower
October 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4951989-erasca-revolutions-approval-just-took-risk-out-of-the-fast-follower
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
October 15 at 1:00 AM  |  Chaikin Analytics (Ad)
ERASCA, INC. (NASDAQ: ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
September 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366747/0/en/erasca-inc-nasdaq-eras-shareholder-investigation-alert-bernstein-liebhard-investigates-potential-breaches-of-fiduciary-duty.html
Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims
September 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/21/3365561/0/en/long-term-shareholders-of-erasca-inc-eras-are-encouraged-to-contact-johnson-fistel-regarding-potential-claims.html
Erasca’s ERAS-601 Trial Completion: What Early Cancer Data Could Mean for Investors
September 16, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/erascas-eras-601-trial-completion-what-early-cancer-data-could-mean-for-investors?utm_source=marketbeat.com&utm_medium=referral
See More Erasca Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Erasca? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Erasca and other key companies, straight to your email.

About Erasca

Erasca (NASDAQ:ERAS) is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancers driven by abnormal signaling in the RAS/MAPK pathway. The company’s research and development activities target tumors with RAS mutations or other alterations that can promote cancer growth and resistance to treatment.

Erasca’s pipeline has included naporafenib, an investigational pan-RAF inhibitor designed to block signaling downstream of RAF proteins, as well as other targeted therapies aimed at genetically defined cancer populations. Its programs are being evaluated in clinical studies, including potential treatments for solid tumors with limited therapeutic options.

Founded in 2018 and headquartered in San Diego, California, Erasca became a publicly traded company on the Nasdaq under the symbol ERAS in 2021. The company is led by co-founder and Chief Executive Officer Jonathan E. Lim, M.D. Its operations are primarily focused on oncology research and clinical development in the United States, with collaborations and trial activities potentially extending to other regions.

View Erasca Profile
Earnings Tools